• 1. 四川大學(xué)華西醫(yī)院循證醫(yī)學(xué)與臨床流行病學(xué)研究中心（成都 610041） 2. 澳大利亞國立大學(xué)，醫(yī)學(xué)院和法律學(xué)院 3. 國家食品與藥品監(jiān)督管理局藥物評(píng)價(jià)中心（北京 100061）;

方法學(xué)質(zhì)量和結(jié)果可適用性是評(píng)價(jià)已發(fā)表藥物經(jīng)濟(jì)學(xué)評(píng)價(jià)研究可靠性和適用性的重要方面，也是影響我國上市后藥物社會(huì)經(jīng)濟(jì)價(jià)值評(píng)價(jià)的因素。本文探討了經(jīng)濟(jì)學(xué)評(píng)價(jià)研究中影響方法學(xué)質(zhì)量和結(jié)果可適用性的因素及其方式，并特別強(qiáng)調(diào)了在我國條件下的影響因素。本文討論了經(jīng)濟(jì)學(xué)評(píng)價(jià)合理的設(shè)計(jì)、實(shí)施和分析和報(bào)道方法，并介紹了現(xiàn)有評(píng)價(jià)經(jīng)濟(jì)學(xué)研究方法學(xué)質(zhì)量量表中，兩種適用于我國的評(píng)價(jià)量表。

引用本文： 孫 鑫,李幼平,Thomas Alured Faunce,程 剛. 上市后藥物經(jīng)濟(jì)學(xué)評(píng)價(jià)方法Ⅲ：影響方法學(xué)質(zhì)量和結(jié)果可適用性的因素. 中國循證醫(yī)學(xué)雜志, 2006, 06(4): 282-291. doi: 復(fù)制

1. Salkeld F, Davey P, Arnolda G. A critical review of health-related economic evaluation in Australia: implications for health policy. Health Policy, 1995;31:111-125.
2. Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies. Soc. Sci. Med,1997;45(4):563-581.
3. Garceau L, Henderson J, Davis LJ, et al. Davidson LL. Economic implications of assisted reproductive techniques: a systematic review. Human reproduction, 2002;17(12):3090-3109.
4. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ, 2000;321;659-664.
5. Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA, 2002;287:2809-2812.
6. Sulpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess, 2004;8(49).
7. Boulenger S, Nixon J, Drummond M, et al. Can economic evaluations be made more trans fer able? Eur J Health Econom, 2005, 6:334–346.
8. Drummond MF, Jefferson TO. On behalf of the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ, 1996;313:275-283.
9. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
10. National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence Handbook series on preparing clinical practice Guidelines. Commonwealth of Australia, 2000.
11. Green C, Brazier J, Deverill M. Valuing Health-Related Quality of Life. A Review of Health State Valuation Techniques. Pharmacoeconomics, 2000; 17 (2): 151-165.
12. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Standardisation of Costs: The Dutch Manual for Costing in Economic Evaluations. Pharmacoeconomics, 2002; 20 (7): 443-454.
13. Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Economics, 1997; 6: 217–227.
14. Birkett DJ, Mitchell AS, McManus P. A Cost-Effectiveness Approach to Drug Subsidy and Pricing in Australia. Health Affairs, 2001; 20(3): 104-114.
15. Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized control trials. Med Care, 1992;30:231–238.
16. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ Economic Evaluation Working Party. BMJ, 1996;313:275–283.
17. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health. 1996. Oxford, Oxford University Press.
18. Nixon J, Pang F. Economic evaluations in Japan: a review of published studies, methodological issues and practice. In: Kondo S, Furuta K (eds) 2000 PSAM 5 – probabilistic safety assessment and management, vol 3. Universal Academy: Tokyo, pp 2077–2084.
19. Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. International Journal of Technology Assessment in Health Care, 2005;21(2):240–245.
20. Shannon S. Critical appraisal of economic analysis studies. Can Assoc Rodiol J, 2002;53(5):251-4.
21. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
22. Chiou CF, Hay JW, Wallace JF, et al. Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies. Medical Care, 2003;41(1):32-44.
23. Gonzalez-Perez JG. Developing a scoring system to quality assess economic evaluations. Eur J Health Econom, 2002;3:131–136.
24. Crowley S, Tognarini D, Desmond P, et al. Introduction of lamivudine for the treatment of chronic hepatitis B: Expected clinical and economic outcomes based on 4-year clinical trial data. Journal of Gastroenterology and Hepatology, 2002; 17:153–164.
  1. 1. Salkeld F, Davey P, Arnolda G. A critical review of health-related economic evaluation in Australia: implications for health policy. Health Policy, 1995;31:111-125.
  2. 2. Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies. Soc. Sci. Med,1997;45(4):563-581.
  3. 3. Garceau L, Henderson J, Davis LJ, et al. Davidson LL. Economic implications of assisted reproductive techniques: a systematic review. Human reproduction, 2002;17(12):3090-3109.
  4. 4. Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ, 2000;321;659-664.
  5. 5. Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA, 2002;287:2809-2812.
  6. 6. Sulpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess, 2004;8(49).
  7. 7. Boulenger S, Nixon J, Drummond M, et al. Can economic evaluations be made more trans fer able? Eur J Health Econom, 2005, 6:334–346.
  8. 8. Drummond MF, Jefferson TO. On behalf of the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ, 1996;313:275-283.
  9. 9. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
  10. 10. National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence Handbook series on preparing clinical practice Guidelines. Commonwealth of Australia, 2000.
  11. 11. Green C, Brazier J, Deverill M. Valuing Health-Related Quality of Life. A Review of Health State Valuation Techniques. Pharmacoeconomics, 2000; 17 (2): 151-165.
  12. 12. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Standardisation of Costs: The Dutch Manual for Costing in Economic Evaluations. Pharmacoeconomics, 2002; 20 (7): 443-454.
  13. 13. Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Economics, 1997; 6: 217–227.
  14. 14. Birkett DJ, Mitchell AS, McManus P. A Cost-Effectiveness Approach to Drug Subsidy and Pricing in Australia. Health Affairs, 2001; 20(3): 104-114.
  15. 15. Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized control trials. Med Care, 1992;30:231–238.
  16. 16. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ Economic Evaluation Working Party. BMJ, 1996;313:275–283.
  17. 17. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health. 1996. Oxford, Oxford University Press.
  18. 18. Nixon J, Pang F. Economic evaluations in Japan: a review of published studies, methodological issues and practice. In: Kondo S, Furuta K (eds) 2000 PSAM 5 – probabilistic safety assessment and management, vol 3. Universal Academy: Tokyo, pp 2077–2084.
  19. 19. Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. International Journal of Technology Assessment in Health Care, 2005;21(2):240–245.
  20. 20. Shannon S. Critical appraisal of economic analysis studies. Can Assoc Rodiol J, 2002;53(5):251-4.
  21. 21. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
  22. 22. Chiou CF, Hay JW, Wallace JF, et al. Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies. Medical Care, 2003;41(1):32-44.
  23. 23. Gonzalez-Perez JG. Developing a scoring system to quality assess economic evaluations. Eur J Health Econom, 2002;3:131–136.
  24. 24. Crowley S, Tognarini D, Desmond P, et al. Introduction of lamivudine for the treatment of chronic hepatitis B: Expected clinical and economic outcomes based on 4-year clinical trial data. Journal of Gastroenterology and Hepatology, 2002; 17:153–164.